IMI2-2014-01-02 - Discovery and validation of novel endpoints in dry age-related macular degeneration and diabetic retinopathy
Specific challenge: Diseases of the retina are among the leading causes of blindness world-wide. Substantial progress has been made in the treatment of neovascular age-related macular degeneration (neovascular AMD) and diabetic macular edema (DME). However, for other common retinal conditions such as the dry form of AMD (dry AMD) or diabetic retinopathy (DR) treatment options remain limited. One major development hurdle is the lack of suitable, patient-relevant study endpoints with clinical relevance for both early exploratory and pivotal trials. Moreover, there are gaps in the understanding on how pre-clinical findings translate into outcomes.
Please refer to the full topic text on the IMI2 Call 1 section of the IMI website: http://www.imi.europa.eu/content/stage-1-13
Scope: The aim is to evaluate novel endpoint candidates for dry AMD and DR. The evaluation should cover the technical, medical and health economic appropriateness of a method and bridge preclinical and clinical studies.
Please refer to the full topic text on the IMI2 Call 1 section of the IMI website.
Expected impact: The project should provide generation of adequate data resulting from robust retrospective and/or prospective studies in patients that could serve as basis for initial discussion with regulatory agencies and/or HTA-bodies for acceptance of the resulting outcomes as endpoints for future clinical programs.Please refer to the full topic text on the IMI2 Call 1 section of the IMI website.